Medicamentos
Categorias
Featured
Mais de 4.000 perfis de medicamentos
Dados moleculares, mecanismos e farmacologia clínica.
Guide Series
Explorar
Reference Content
Comparações
Análises comparativas de medicamentos
Percursos de Medicamentos
Narrativas ADME
Famílias de Medicamentos
Relações estruturais SAR
Momentos decisivos que moldaram a farmacologia moderna — descobertas, avanços e lições aprendidas.
Morphine's isolation established the field of alkaloid chemistry and proved that pure chemical compounds underlie the activity of crude plant drugs. This principle—that pharmacologically active …
Aspirin exemplifies the pharmaceutical optimisation of a natural product: chemical modification converted an effective but irritating compound into a tolerated drug. It also illustrates how …
Receptor theory transformed pharmacology from a descriptive to a mechanistic science. The concept that drugs act by binding to specific molecular targets—and that [[term:selectivity|selectivity]] for …
Penicillin's discovery and development created the antibiotic era, reducing mortality from bacterial infections that had been uniformly fatal. It also established the natural product screening …
The Sulfanilamide Disaster directly created the modern drug safety regulatory framework. The Federal Food, Drug, and Cosmetic Act of 1938 established the pre-market safety approval …
Industrial penicillin production established the fermentation technology and pharmaceutical manufacturing infrastructure that underpins the production of antibiotics, vitamins, amino acids, and eventually recombinant biologics. It …
Streptomycin provided the first effective treatment for tuberculosis, one of history's deadliest infectious diseases. The 1948 MRC streptomycin trial established the randomised controlled trial as …
Ahlquist's receptor classification provided the theoretical basis for selective adrenergic drugs— beta-blockers, alpha-blockers, and selective beta-agonists for asthma. It demonstrated that receptor subtype [[term:selectivity|selectivity]] could …
Chlorpromazine founded biological psychiatry and created the field of psychopharmacology. It demonstrated that severe psychiatric illness had a biological substrate amenable to pharmacological intervention, shifted …
Imipramine established depression as a biologically treatable illness and founded the tricyclic antidepressant class. Its mechanism underpinned the monoamine hypothesis of depression, which— despite its …
Thalidomide's teratogenic catastrophe revealed that drugs can have completely different toxicological profiles across species and developmental stages, revolutionised preclinical reproductive toxicology requirements, and established that …
The Kefauver-Harris Amendment established [[term:efficacy|efficacy]] as a regulatory requirement alongside safety, making the randomised controlled trial central to drug approval globally. Its framework—pre-clinical testing, IND …
Propranolol validated receptor-targeted drug design as a strategy—demonstrating that systematic application of receptor pharmacology to a defined clinical need could produce a world-changing drug. The …
Vane's discovery of aspirin's mechanism founded modern eicosanoid pharmacology and established prostaglandins as key mediators of inflammation, pain, and fever. It led directly to the …
Hybridoma technology made it possible to produce unlimited quantities of a precisely defined antibody, transforming diagnostics and creating the largest and fastest-growing class of biopharmaceuticals. …
Cimetidine was the first drug deliberately designed by rational receptor-pharmacology methodology to achieve commercial and clinical success, validating Black's approach and demonstrating that rational drug …
Captopril was the first drug designed using the structure of a target enzyme's active site— inaugurating structure-based drug design as a practical drug discovery strategy. …
Recombinant insulin proved that genetic engineering could produce therapeutic human proteins at commercial scale with acceptable safety—founding the biotechnology pharmaceutical industry. Its approval established the …
Muromonab-CD3's approval opened the regulatory pathway and established clinical proof-of-concept for all subsequent therapeutic monoclonal antibodies. Its limitations—murine immunogenicity and cytokine release syndrome—directly drove the …
AZT demonstrated that HIV replication could be pharmacologically inhibited, transforming AIDS from a uniformly fatal illness into a treatable condition—though full therapeutic transformation awaited combination …
Lovastatin inaugurated the statin era, which produced the most robust cardiovascular mortality reduction data of any drug class. Statins demonstrated that sustained LDL lowering translates …
Fluoxetine demonstrated that SERT [[term:selectivity|selectivity]] could produce antidepressant [[term:efficacy|efficacy]] with a safety and tolerability profile that made treatment of depression practical for primary care physicians. …
Omeprazole established proton pump inhibition as the dominant strategy for acid suppression, achieving more profound and sustained gastric acid reduction than H2 antagonists and enabling …
Saquinavir validated structure-based drug design against a viral enzyme and provided the first [[term:protease-inhibitor|protease inhibitor]] building block for HAART, which transformed HIV/AIDS from a death …
Rituximab was the first approved anti-cancer [[term:monoclonal-antibody|monoclonal antibody]], proving that Ehrlich's magic bullet concept was clinically achievable. It established CD20 as a validated oncology target, …
Sildenafil illustrated that rigorous attention to unexpected clinical signals during trials can salvage—and dramatically redirect—a failing programme. It created the PDE5 inhibitor drug class, established …
Trastuzumab demonstrated that an oncogenic driver gene—present in a defined patient subset— could be pharmacologically silenced with a [[term:monoclonal-antibody|monoclonal antibody]], dramatically improving outcomes in a …
Imatinib proved the concept that a single oncogenic kinase can be pharmacologically silenced by a small molecule, converting a lethal leukaemia into a manageable chronic …
Completing the human genome reference sequence provided the foundational resource for all subsequent genomic medicine: GWAS, [[term:pharmacogenomics|pharmacogenomics]], rare-disease gene discovery, and cancer genomics. It catalysed …
The rofecoxib withdrawal reshaped [[term:pharmacovigilance|pharmacovigilance]] globally, prompting mandatory post-marketing commitments, expanded use of FDA's Sentinel System for real-world safety monitoring, and more stringent cardiovascular risk …
Bevacizumab validated Judah Folkman's angiogenesis hypothesis after three decades of controversy and launched the anti-VEGF drug class. It established tumour vasculature as a legitimate therapeutic …
Gardasil established that a vaccine could prevent a human malignancy by eliminating the causative infectious agent. It validated the VLP platform as safe and highly …
Ipilimumab proved that releasing immunological brakes could produce durable tumour regression and long-term survival in a cancer previously resistant to all systemic therapy. It established …
Sofosbuvir made chronic hepatitis C—a major global cause of cirrhosis and hepatocellular carcinoma affecting 70 million people—curable with a short oral course in virtually all …
The 2013 CAR-T results demonstrated that genetically engineered autologous immune cells could achieve deep and durable complete remissions in patients with haematological malignancies refractory to …
PD-1 blockade extended checkpoint immunotherapy to a much broader range of tumour types than CTLA-4 inhibition, demonstrating that blocking immunosuppressive signals within the tumour microenvironment …
The 2015 debates crystallised [[term:crispr-drug-discovery|CRISPR]]-Cas9 as both the most powerful genome-editing tool yet available and the focal point of the most consequential bioethical deliberation in …
Kymriah's approval established [[term:car-t-cell-therapy|CAR-T cell therapy]] as a commercial medical product, creating the first approved gene therapy for cancer and demonstrating that a personalised, patient-derived …
Luxturna proved that an AAV vector could deliver a functional gene in vivo and restore meaningful physiological function in a human genetic disease, validating in …
Patisiran validated RNAi as a therapeutic mechanism and lipid nanoparticle as a clinical delivery vehicle, establishing RNA-based therapeutics as a viable pharmacological class. It demonstrated …
mRNA COVID-19 vaccines demonstrated that a nucleic acid platform could be designed, scaled, and authorised at population scale in under one year, achieving [[term:efficacy|efficacy]] rates …
Aducanumab's approval and subsequent withdrawal crystallised the debate over whether amyloid plaque reduction constitutes a valid [[term:surrogate-endpoint|surrogate endpoint]] for Alzheimer's clinical benefit, ultimately strengthening the …
AlphaFold2 solved the protein structure prediction problem at proteome scale, providing free high-accuracy structural models for virtually every known protein. This transformed structure- based drug …
Evusheld demonstrated that long-acting [[term:monoclonal-antibody|monoclonal antibody]] combinations with Fc-extended [[term:half-life|half-life]] could provide months of prophylactic protection against respiratory viral infection, establishing a template for passive …
Semaglutide at 2.4 mg demonstrated that pharmacological appetite regulation could achieve clinically meaningful weight reduction approaching surgical outcomes, repositioning obesity from a lifestyle issue to …
Casgevy's approval realised the clinical potential of [[term:crispr-drug-discovery|CRISPR]]-Cas9 gene editing in human patients, demonstrating durable functional cure of two severe inherited haemoglobin disorders through a …
Lecanemab became the first Alzheimer's therapy to demonstrate both amyloid [[term:clearance|clearance]] and statistically significant slowing of clinical decline in a prospectively designed Phase III trial …
The multi-indication expansion of GLP-1 agonists revealed a mechanistic pleiotropy—metabolic, anti-inflammatory, cardiovascular, renal, and neurological—that fundamentally repositioned the drug class from diabetes management to broad …
The first [[term:protac|PROTAC]] to enter Phase III trials represented the clinical validation of targeted protein degradation as a therapeutic modality distinct from enzymatic inhibition, expanding …
The advance of AI-generated drug candidates into Phase II trials demonstrated that artificial intelligence can meaningfully compress the drug discovery timeline—from years to months—by integrating …